The landscape of chronic illness treatment is shifting as researchers move beyond mere symptom management toward addressing the biological roots of exhaustion. As we move through 2026, a clear trend has emerged: rapamycin, once known primarily as a transplant drug and longevity "miracle," is being repurposed as a precision tool for patients battling Long COVID…

People are tracking the latest breakthroughs in clinical longevity, already know that rapamycin has shifted from a niche immunosuppressant to the most heavily debated molecule in geroscience. But exactly why would a doctor prescribe rapamycin today? For decades, the FDA has approved rapamycin (known generically as sirolimus) specifically to prevent organ transplant rejection and treat…

The translation of mammalian target of rapamycin (mTOR) inhibitors from preclinical models to human longevity interventions is the most scrutinized frontier in modern geroscience. We are moving far beyond the theoretical question of if rapamycin extends lifespan. Decades of data confirm its efficacy across yeast, nematodes, fruit flies, and mice. Today, the clinical challenge is…

The study of the Mechanistic Target Of Rapamycin (mTOR) has evolved from a curious discovery in Easter Island soil to the cornerstone of modern longevity science. While early research focused on its immunosuppressive properties, current clinical interest centers on its role as the "master regulator" of cellular growth and aging. Understanding the precise structural mechanism…